Icotrokinra vs Ipamorelin
Overview
Icotrokinra is primarily a immune support peptide, while Ipamorelin is used for performance & growth.
This page compares Icotrokinra and Ipamorelin across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Icotrokinra | Ipamorelin | |
|---|---|---|
| Category | Immune Support | Performance & Growth |
| Regulatory status (US) | FDA approved | Research use only |
| Typical dosage | — | 200-300 mcg |
| Frequency | — | twice-daily |
| Reported benefits | — | Natural GH release, improved body composition, better sleep, anti-aging effects, no appetite increase |
| Reported side effects | — | Very well-tolerated. Rare: headache, injection site reactions |
Key differences
Primary use. Icotrokinra is categorised under Immune Support, while Ipamorelin falls under Performance & Growth. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Icotrokinra: FDA-approved. Ipamorelin: not FDA-approved; treated as a research compound.
Dosing. Typical dosing for Icotrokinra is not catalogued. Ipamorelin is typically dosed at 200-300 mcg (twice-daily).
Can you stack them?
Some protocols combine peptides, but stacking Icotrokinra and Ipamorelin has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Icotrokinra and Ipamorelin?
- Icotrokinra is primarily a immune support peptide, while Ipamorelin is used for performance & growth. Icotrokinra is FDA-approved for one or more indications, whereas Ipamorelin is not FDA-approved; generally classified as a research compound.
- What is Icotrokinra used for?
- Oral macrocyclic peptide. First-in-class IL-23 receptor antagonist. FDA approved March 17, 2026 for plaque psoriasis.
- What is Ipamorelin used for?
- GH secretagogue, anti-aging.
- Can you take Icotrokinra and Ipamorelin together?
- Some users combine peptides within a single protocol, but stacking Icotrokinra and Ipamorelin has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Icotrokinra or Ipamorelin FDA-approved?
- Icotrokinra is FDA-approved for one or more indications. Ipamorelin is not FDA-approved; generally classified as a research compound.
Read the full articles
- Icotrokinra — full monograph: mechanism, research, dosing & references
- Ipamorelin — full monograph: mechanism, research, dosing & references